Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Breast Cancer Research : BCR|April 2, 2014
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerJasmeet Singh, Yelena Novik, Stacey Stein, et al.
Journal of the National Cancer Institute|February 1, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A Emens, Luciana Molinero, Sherene Loi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancerSylvia Adams, Lina Kozhaya, Frank Martiniuk, et al.
Cancer Immunity|July 13, 2007
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factorsElsa F Velazquez, Achim A Jungbluth, Molly Yancovitz, et al.
Magnetic Resonance in Medicine|October 26, 2016
Voxelwise analysis of simultaneously acquired and spatially correlated 18 F-fluorodeoxyglucose (FDG)-PET and intravoxel incoherent motion metrics in breast cancerJason Ostenson, Akshat C Pujara, Artem Mikheev, et al.
Breast Cancer Research and Treatment|November 11, 2017
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancerMaryann Kwa, Xiaochun Li, Yelena Novik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2018
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast CancerSilvia C Formenti, Percy Lee, Sylvia Adams, et al.
Neurosurgery|August 15, 2023
Long-term Survival From Breast Cancer Brain Metastases in the Era of Modern Systemic TherapiesElad Mashiach, Juan Diego Alzate, Fernando De Nigris Vasconcellos, et al.
Molecular Cell|November 5, 2020
Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase εVladislav O Sviderskiy, Lili Blumenberg, Elizabeth Gorodetsky, et al.
Journal of the National Cancer Institute|June 7, 2021
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast CancerHope S Rugo, Sherene Loi, Sylvia Adams, et al.
Pageof 10